In Vivo Evaluation of Pam<sub>2</sub>Cys‐Modified Cancer‐Testis Antigens as Potential Self‐Adjuvanting Cancer Vaccines
Peptide-based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more effective opportunity to covalently and regioselectively graft immunostimulatory motifs directly onto the antigen scaffold to yield self-adjuvanting vaccines. Herein, we explore the synthesis of two tissue-restricted cancer-testis antigens (CTAs); New York oesophageal cell carcinoma 1 (NY-ESO-1) and B melanoma antigen 4 (BAGE4), both carrying the toll-like receptor (TLR) agonist, Pam<sub>2</sub>Cys. These constructs were evaluated in vivo along with a lipid nanoparticle (LNP) preparation of the underexplored BAGE4 melanoma antigen.
Authors
- Nicholas J. Mitchell (ORCID: https://orcid.org/0000-0002-9041-1852)
- Ian W. Hamley (ORCID: https://orcid.org/0000-0002-4549-0926)
- Jani Seitsonen
- Valeria Castelletto (ORCID: https://orcid.org/0000-0002-3705-0162)
- Salwa Aljohani
- Peter Symonds
- Victoria A. Brentville (ORCID: https://orcid.org/0000-0003-2000-5629)
- Lindy G. Durrant (ORCID: https://orcid.org/0000-0002-7217-3707)
- Alex G. Edmonds (ORCID: https://orcid.org/0009-0005-5139-8666)
Institutions
- University of Nottingham (GB)
- University of Reading (GB)
- Aalto University (FI)
Publication Details
- Journal
- Journal of Peptide Science
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1002/psc.70022
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UK Research and Innovation
- Leverhulme Trust
- Taibah University
- Engineering and Physical Sciences Research Council